
    
      This Phase 1 clinical trial will be a single dose pharmacokinetics study comprised of 21
      individuals with five blood draws over a 12 hour period. Additionally, subjects will
      subjectively score symptom relief and report any side effects from the single dose of AHIST.
      Schulman Associates Institutional Review Board (Cincinnati, OH) will approve the study
      protocol and statement of informed consent. Each study participant will give written informed
      consent (See Attachment A). Safety will be assured through close observation and physical
      examination of subjects before, during and at study conclusion. This interventional study
      will be conducted during the spring allergy season of 2010.

      MAGNA plans to show that chlorpheniramine tannate is a safe and effective B.I.D. drug
      treatment regimen, "indicated for the relief of symptoms associated with seasonal allergic
      rhinitis in adults and children 12 years of age and older. Treated symptoms include nasal
      congestion, sneezing, rhinorrhea, itchy nose, itchy/watery eyes, and post nasal drip syndrome
      [reduction in tickly cough (acute or chronic), mucus in the back of the throat, sore throat,
      and hoarseness]."
    
  